Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus

Investment analysts at Stifel Nicolaus began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) in a report released on Tuesday, MarketBeat reports. The firm set a “buy” rating and a $21.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 39.53% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Bank of America upped their target price on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Finally, HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.56.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $15.05 on Tuesday. The stock has a market capitalization of $1.65 billion, a P/E ratio of -9.71 and a beta of -0.31. The company’s 50 day simple moving average is $13.88 and its 200-day simple moving average is $13.17. Amylyx Pharmaceuticals has a one year low of $3.00 and a one year high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. As a group, analysts anticipate that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insider Activity

In other Amylyx Pharmaceuticals news, Director Karen Firestone bought 8,100 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average cost of $12.45 per share, with a total value of $100,845.00. Following the completion of the purchase, the director owned 63,100 shares in the company, valued at approximately $785,595. The trade was a 14.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Justin B. Klee sold 1,995 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total value of $27,710.55. Following the sale, the chief executive officer directly owned 3,379,398 shares in the company, valued at approximately $46,939,838.22. This represents a 0.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 151,203 shares of company stock worth $2,028,385 in the last 90 days. Corporate insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its holdings in Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after buying an additional 143,065 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth about $149,000. Acadian Asset Management LLC boosted its stake in shares of Amylyx Pharmaceuticals by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock worth $3,645,000 after buying an additional 326,976 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $113,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

More Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $34 and maintained a buy rating, representing meaningful upside vs. the current price and signalling increased analyst confidence. HC Wainwright raises price target to $34
• Positive Sentiment: Stifel Nicolaus initiated coverage with a “buy” rating and a $21 price target, adding another institutional positive viewpoint on the stock. Stifel starts coverage, $21 PT
• Positive Sentiment: Q4 2025 results slightly beat estimates (EPS -$0.30 vs. consensus -$0.31) and management provided financials/updates in the earnings release — small fundamental beat that supports sentiment. Amylyx Q4 2025 press release
• Positive Sentiment: Company and analysts are refocusing investment thesis on avexitide (GLP‑1 receptor antagonist) with Phase 3 LUCIDITY topline expected in Q3 2026; Amylyx also reports a strong cash position (~$317M) projected to fund operations into 2028 — supports runway to key value‑creating milestones. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Neutral Sentiment: Market commentary and valuation pieces are re‑examining Amylyx after reduced losses and late‑stage pipeline progress; useful for framing risk/reward but not an immediate catalyst. A Look At Amylyx Valuation
• Neutral Sentiment: Reported short‑interest data for early March appears inconsistent (shows zero shares / NaN changes); there’s no clear evidence of a meaningful short squeeze or buildup based on the provided figures.
• Negative Sentiment: Analyst downgrade from “Strong Buy” to “Buy” and the discontinuation of AMX0035 for PSP reduce optionality from that program — this narrows the pipeline and was cited as the reason for the softer rating. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.